The role of microRNAs to understand sex-based differences in Alzheimer’s disease
暂无分享,去创建一个
Marta R. Hidalgo | F. Guerini | H. Carceller | R. Mancuso | Zoraida Andreu | Irene Soler-Sáez | F. Gordillo | J. Llera-Oyola | B. Roson | Akiko Mizokami | María de la Iglesia-Vayá | Francisco García-García
[1] Marta R. Hidalgo,et al. A deep transcriptome meta-analysis reveals sex differences in multiple sclerosis , 2023, Neurobiology of Disease.
[2] B. F. Mogharbel,et al. State of the Art of microRNAs Signatures as Biomarkers and Therapeutic Targets in Parkinson’s and Alzheimer’s Diseases: A Systematic Review and Meta-Analysis , 2023, Biomedicines.
[3] H. Changotra,et al. Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease , 2022, Molecular Neurobiology.
[4] A. Koyanagi,et al. Differential expression of MicroRNAs in Alzheimer’s disease: a systematic review and meta-analysis , 2022, Molecular Psychiatry.
[5] Bin Wang,et al. CircAXL Knockdown Alleviates Aβ1-42-Induced Neurotoxicity in Alzheimer’s Disease via Repressing PDE4A by Releasing miR-1306-5p , 2022, Neurochemical Research.
[6] W. Liang,et al. Inhibiting microRNA-142–5p improves learning and memory in Alzheimer’s disease rats via targeted regulation of the PTPN1-mediated Akt pathway , 2022, Brain Research Bulletin.
[7] In Soo Ryu,et al. miRNAs as Therapeutic Tools in Alzheimer’s Disease , 2021, International journal of molecular sciences.
[8] D. Galimberti,et al. Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease , 2021, Pharmaceuticals.
[9] Marta R. Hidalgo,et al. Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies , 2021, Biology of Sex Differences.
[10] K. Ozaki,et al. Dementia subtype prediction models constructed by penalized regression methods for multiclass classification using serum microRNA expression data , 2021, Scientific Reports.
[11] A. Dhawan. Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful? , 2021, Biomarkers in medicine.
[12] Li-Li Ji,et al. miR-142 downregulation alleviates the impairment of spatial learning and memory, reduces the level of apoptosis, and upregulates the expression of pCaMKII and BAI3 in the hippocampus of APP/PS1 transgenic mice , 2021, Behavioural Brain Research.
[13] T. Strovas,et al. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease , 2021, Acta Neuropathologica Communications.
[14] A. Carè,et al. A Sex Perspective in Neurodegenerative Diseases: microRNAs as Possible Peripheral Biomarkers , 2021, International journal of molecular sciences.
[15] L. Tan,et al. The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention , 2021, The Journal of Prevention of Alzheimer's Disease.
[16] Jacob I. Ayers,et al. Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components , 2021, Neuron.
[17] Marta R. Hidalgo,et al. Hepatic steatosis and steatohepatitis: a functional meta-analysis of sex-based differences in transcriptomic studies , 2021, Biology of sex differences.
[18] Bin Zhang,et al. Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape , 2021, Biological Psychiatry.
[19] Anushya Muruganujan,et al. The Gene Ontology resource: enriching a GOld mine , 2020, Nucleic Acids Res..
[20] Christopher J. Tonkin,et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS , 2020, Cell.
[21] C. Reitz,et al. Late-onset vs nonmendelian early-onset Alzheimer disease , 2020, Neurology: Genetics.
[22] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[23] Z. Hojati,et al. The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer’s Disease , 2020, Iranian biomedical journal.
[24] Marta R. Hidalgo,et al. Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies , 2020, medRxiv.
[25] Zhi-Yong Wang,et al. MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers , 2020, Frontiers in Molecular Neuroscience.
[26] Marta R. Hidalgo,et al. Unveiling Sex-Based Differences in the Effects of Alcohol Abuse: A Comprehensive Functional Meta-Analysis of Transcriptomic Studies , 2020, bioRxiv.
[27] Keith A. Johnson,et al. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline , 2020, Annals of neurology.
[28] K. Barve,et al. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease , 2020, Current neuropharmacology.
[29] C. Gravholt,et al. What microRNAs could tell us about the human X chromosome , 2020, Cellular and Molecular Life Sciences.
[30] N. Zhang,et al. Berberine attenuates Aβ42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells. , 2020, Life sciences.
[31] Zhu Chen,et al. Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer’s Disease: A Pilot Study , 2020, Neuroscience.
[32] R. Perneczky,et al. Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid , 2019, Alzheimer's & Dementia.
[33] Nick C Fox,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[34] Nicholas M. Wragg,et al. Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease , 2019, Molecular Neurobiology.
[35] Ana Kozomara,et al. miRBase: from microRNA sequences to function , 2018, Nucleic Acids Res..
[36] Nuno A. Fonseca,et al. ArrayExpress update – from bulk to single-cell expression data , 2018, Nucleic Acids Res..
[37] S. Aoki,et al. The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology , 2018, Molecular Psychiatry.
[38] Ketan S. Patil,et al. Cellular Proteostasis in Neurodegeneration , 2018, Molecular Neurobiology.
[39] C. Peng,et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation , 2018, Front. Endocrinol..
[40] M. Mesulam,et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.
[41] W. Noble,et al. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies , 2018, Acta Neuropathologica Communications.
[42] L. Rajendran,et al. Microglia-Mediated Synapse Loss in Alzheimer's Disease , 2018, The Journal of Neuroscience.
[43] A. Carè,et al. Sex disparity in cancer: roles of microRNAs and related functional players , 2018, Cell Death & Differentiation.
[44] L. Milanesi,et al. The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading , 2017, Genome Biology.
[45] M. Mendez. Early-Onset Alzheimer Disease. , 2017, Neurologic clinics.
[46] K. Sandberg,et al. How to study the impact of sex and gender in medical research: a review of resources , 2016, Biology of Sex Differences.
[47] Ru-jing Ren,et al. Diagnostic Value of microRNA for Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2016, Front. Aging Neurosci..
[48] Russell Bowler,et al. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations , 2014, Nucleic acids research.
[49] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[50] G. Barry. Integrating the roles of long and small non-coding RNA in brain function and disease , 2014, Molecular Psychiatry.
[51] Aikaterini S. Papadopoulou,et al. Alteration of the microRNA network during the progression of Alzheimer's disease , 2013, EMBO molecular medicine.
[52] Sabine C. Mueller,et al. A blood based 12-miRNA signature of Alzheimer disease patients , 2013, Genome Biology.
[53] Stefan L Ameres,et al. Diversifying microRNA sequence and function , 2013, Nature Reviews Molecular Cell Biology.
[54] S. Hauser. Harrison's Neurology in Clinical Medicine , 2013 .
[55] Sean R. Davis,et al. NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..
[56] T. Gale,et al. Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis , 2012, Journal of clinical and experimental neuropsychology.
[57] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[58] Michael W. Weiner,et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans , 2010, Neurobiology of Aging.
[59] J. Dopazo,et al. Multidimensional Gene Set Analysis of Genomic Data , 2010, PloS one.
[60] Juan Nunez-Iglesias,et al. Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease Cortex Reveals Altered miRNA Regulation , 2010, PloS one.
[61] E. Birney,et al. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.
[62] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[63] T. Gale,et al. Sex differences in Alzheimer's disease , 2018, Current opinion in psychiatry.
[64] M. Robinson,et al. Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. , 2018, Journal of Alzheimer's disease : JAD.
[65] W. Rocca. Time, Sex, Gender, History, and Dementia. , 2017, Alzheimer disease and associated disorders.
[66] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[67] A. Andreadis. Misregulation of tau alternative splicing in neurodegeneration and dementia. , 2006, Progress in molecular and subcellular biology.
[68] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .